umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Emerging Trend in the Pharmacotherapy of Osteoarthritis
Umeå University, Faculty of Medicine, Department of Integrative Medical Biology (IMB). School of Medicine, Southeast University, Nanjing, China.
Show others and affiliations
2019 (English)In: Frontiers in Endocrinology, ISSN 1664-2392, E-ISSN 1664-2392, Vol. 10, article id 431Article, review/survey (Refereed) Published
Abstract [en]

Osteoarthritis (OA) is a degenerative joint disorder and one of the most prevalent diseases among the elderly population. Due to the limited spontaneous healing capacity of articular cartilage, it still remains challenging to find satisfactory treatment for OA. This review covers the emerging trends of pharmacologic therapies for OA such as traditional OA drugs (acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), opioids, serotonin-norepinephrine reuptake inhibitors (SNRIs), intra-articular injections of corticosteroids, and dietary supplements), which are effective in pain relief but not in reversing damage, and are frequently associated with adverse events. Alternatively, disease-modifying drugs provide promising alternatives for the management of OA. The development of these emerging OA therapeutic agents requires a comprehensive understanding of the pathophysiology of OA progression. The process of cartilage anabolism/catabolism, subchondral bone remodeling and synovial inflammation are identified as potential targets. These emerging OA drugs such as bone morphogenetic protein-7 (BMP-7), fibroblast growth factor-18 (FGF-18), human serum albumin (HSA), interleukin-1 (IL-1) inhibitor, h-Nerve growth factor (beta-NGF) antibody, matrix extracellular phosphoglycoprotein (MERE) and inverse agonist of retinoic acid-related orphan receptor alpha (ROR alpha) etc. have shown potential to modify progression of OA with minimal adverse effects. However, large-scale randomized controlled trials (RCTs) are needed to investigate the safety and efficacy before translation from bench to bedside.

Place, publisher, year, edition, pages
Frontiers Media S.A., 2019. Vol. 10, article id 431
Keywords [en]
osteoarthritis, articular cartilage, clinical trials, pharmacologic therapy, regenerative therapy
National Category
Endocrinology and Diabetes
Identifiers
URN: urn:nbn:se:umu:diva-161697DOI: 10.3389/fendo.2019.00431ISI: 000473637500002OAI: oai:DiVA.org:umu-161697DiVA, id: diva2:1340490
Available from: 2019-08-05 Created: 2019-08-05 Last updated: 2019-08-05Bibliographically approved

Open Access in DiVA

fulltext(572 kB)37 downloads
File information
File name FULLTEXT01.pdfFile size 572 kBChecksum SHA-512
47aac0d122c6991c68c07f40a3cacb4378786ae3f8f4b052263a05035be0cff4b7f57fb7fa9e101dae5bd725f7bef73a37ebec0fac112caa0e06a4fad5d43289
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Authority records BETA

Zhang, Wei

Search in DiVA

By author/editor
Zhang, Wei
By organisation
Department of Integrative Medical Biology (IMB)
In the same journal
Frontiers in Endocrinology
Endocrinology and Diabetes

Search outside of DiVA

GoogleGoogle Scholar
Total: 37 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 84 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf